

## ABIVAX to participate in the upcoming RBC Capital Markets 2016 Healthcare Conference in New York, and in the Credit Suisse Healthcare Conference in London

February 11, 2016

Details

Published on Thursday, 11 February 2016 17:00

Paris, France, February 11<sup>th</sup>, 2016 – ABIVAX (Euronext Paris: FR0012333284 – ABVX), an emerging leader in developing and commercializing anti-viral drugs and therapeutic vaccines for diseases like HIV/AIDS and chronic hepatitis B (CHB), today announced that its CEO, Prof. Hartmut Ehrlich, M.D., will participate in the RBC Capital Markets 2016 Healthcare Conference in New York on February 23<sup>rd</sup> and 24<sup>th</sup>, and in the Credit Suisse Healthcare Conference in London on March 1<sup>st</sup> and 2<sup>nd</sup>.